What are the treatment guidelines for low-risk myelodysplastic syndrome (MDS)?

Updated: Jul 24, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print

In lower-risk MDS patients, all three guidelines recommend the following for treatment of symptomatic anemia [24, 40, 39]

  • Patients without del(5q): Erythropoiesis-stimulating agents (ESAs); recombinant erythropoietin (EPO) or darbepoetin (DAR); granulocyte colony-stimulating factor (G-CSF) may be added
  • Patients with del(5q):  Lenalidomide

For patients with neutropenia and thrombocytopenia, NCCN guidelines recommend azacitidine/decitabine or immunosuppressive therapy in selected cases. [24]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!